Categories: News

Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, is scheduled to participate in a virtual fireside chat at the Bank of America Securities 2022 Precision Oncology Conference on Monday, October 3, 2022, at 2:50 p.m. ET. The fireside chat will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the presentation.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of disparate technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.

Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

Staff

Recent Posts

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a…

52 mins ago

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale…

53 mins ago

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical ScenariosLATHAM, N.Y.--(BUSINESS…

54 mins ago

Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

The leading benefits solution and largest infertility advocacy non-profit will host a series of events…

55 mins ago

Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024

Hamilton, Bermuda, April 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company")…

55 mins ago